When should a FibroScan be recommended?

When to Recommend FibroScan

FibroScan should be recommended for all patients with chronic hepatitis B to stage liver fibrosis and guide antiviral treatment decisions, using cutoffs of >7.0 kPa for significant fibrosis (≥F2) and >12.5 kPa for cirrhosis (F4) per 2024 WHO guidelines 1.

Primary Indications by Disease Category

Chronic Hepatitis B (Strongest Evidence)

• All patients with chronic HBV infection require FibroScan to determine treatment eligibility 1
• Use >7.0 kPa to identify significant fibrosis (≥F2) - these patients are priority for antiviral therapy 1
• Use >12.5 kPa to identify cirrhosis (F4) - these patients require immediate treatment and hepatocellular carcinoma surveillance 1
• Repeat FibroScan during follow-up in untreated patients (chronic hepatitis with no treatment criteria, inactive carriers, immune-tolerant phase) to monitor for disease progression 2
• Continue monitoring even after successful antiviral therapy in those with previous advanced fibrosis/cirrhosis 3

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD)

• Screen all patients with metabolic risk factors (obesity, central adiposity, diabetes, ALT >2× upper limit of normal) 4, 5
• Use FIB-4 score first as initial screening tool in primary care 4
• Proceed to FibroScan when FIB-4 is elevated or indeterminate 4
• Use <10 kPa to rule out compensated advanced chronic liver disease (cACLD) 3
• Use ≥15 kPa as highly suggestive of cACLD 3
• Gray zone (10-15 kPa): combine with platelet count - if <15 kPa AND platelets >150,000, can rule out cACLD 3

Chronic Hepatitis C

• All patients with HCV - both for initial staging and post-treatment monitoring 6, 7
• Particularly valuable in HIV-HCV co-infected patients 6
• Monitor for recurrence after liver transplantation 6

Alcohol-Related Liver Disease

• All patients with harmful alcohol use and abnormal liver tests 4
• Screen those with persistent risk factors even after alcohol cessation 3

Previously Treated Viral Hepatitis

• HBV patients: HBsAg negative, HBcAb positive (with or without HBsAb), HBV-DNA negative 3
• HCV patients: HCVAb positive, HCV-RNA negative 3
• Perform FibroScan if:
  • Persistent hepatocellular injury (elevated AST, ALT, GGT, ALP) 3
  • Other risk factors present (alcohol, metabolic syndrome) 3
  • Any clinical or imaging signs of advanced liver disease 3

Congenital Bleeding Disorders

• All patients with previous HBV/HCV exposure should undergo hepatological evaluation including FibroScan 3
• Screen those with metabolic risk factors even without viral hepatitis history 3

Critical Interpretation Points

Technical Requirements for Valid Results

• Ensure adequate number of measurements with acceptable success rate 7
• Check interquartile range - must be within acceptable limits 7
• Repeat if suspicious results 7
• Failure rate ~4-5%, mainly in obese patients 2, 6

Factors That Increase Liver Stiffness (Beyond Fibrosis)

• Acute transaminase elevation: increases stiffness by 1.2-4.4 times 2
• Active inflammation/necroinflammation during HBV reactivation 2
• Congestive hepatopathy 8
• Interpret values in context of ALT levels - add 1-2 kPa to cutoffs when transaminases are elevated 2

Disease-Specific Cutoff Adjustments

Hepatitis B has LOWER cutoffs than Hepatitis C due to macronodular cirrhosis with less fibrous tissue 2:

• Not significant: <6 kPa
• Gray area: 6-9 kPa
• Significant fibrosis: >9 kPa
• Cirrhosis: >12 kPa (add 1-2 kPa if high transaminases) 2

Common Pitfalls to Avoid

1. Do NOT use FibroScan alone in low-prevalence populations - positive predictive value is poor (only 29% truly have cirrhosis when prevalence is 5%) 5

2. Do NOT skip comprehensive liver disease workup - FibroScan measures stiffness, not just fibrosis; must interpret with clinical, biochemical, and imaging data 6

3. Do NOT assume FibroScan distinguishes adjacent fibrosis stages - excellent for F0-1 vs F2-4 or cirrhosis vs non-cirrhosis, but poor for intermediate stages 9

4. Do NOT ignore false negatives - in HBV with ALT <2× ULN, some patients with significant fibrosis may have normal stiffness 10

5. Do NOT use same cutoffs across all liver diseases - HBV requires lower thresholds than HCV 2

Practical Algorithm for Primary Care

1. Identify risk factors: metabolic syndrome, alcohol use, HBV, HCV, family history
2. Check labs: AST, ALT, GGT, ALP, platelet count
3. Calculate FIB-4 (if metabolic/alcohol only)
4. If FIB-4 elevated OR viral hepatitis present: order FibroScan
5. If FibroScan suggests advanced fibrosis/cirrhosis: refer to hepatology 4

Advantages Over Liver Biopsy

• Non-invasive with no complications 2, 6
• Repeatable for longitudinal monitoring 2
• Samples 100× larger tissue volume than biopsy 2
• Immediate results at bedside or outpatient clinic 6
• Good reproducibility 6
• Cost-effective - takes <10 minutes, trainable for non-physicians 1

The 2024 WHO guidelines represent a paradigm shift toward lower cutoffs that prioritize minimizing false negatives (missing patients who need treatment) over false positives, accepting that ~16-26% may be overtreated to ensure only 6-7% with significant disease are missed 1. This approach prioritizes preventing progression to cirrhosis and hepatocellular carcinoma over avoiding unnecessary treatment.